AxoGen, Inc. (NASDAQ:AXGN) Given Average Recommendation of “Buy” by Analysts

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been given an average rating of “Buy” by the five ratings firms that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.80.

Several equities research analysts recently commented on AXGN shares. Raymond James started coverage on shares of AxoGen in a research report on Monday, July 1st. They issued an “outperform” rating and a $13.00 price objective on the stock. JMP Securities upped their target price on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, August 9th. StockNews.com lowered shares of AxoGen from a “buy” rating to a “hold” rating in a report on Monday. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $15.00 target price on shares of AxoGen in a report on Thursday, June 20th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Koss Olinger Consulting LLC acquired a new position in shares of AxoGen during the 2nd quarter valued at about $75,000. Lazard Asset Management LLC increased its stake in shares of AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 2,671 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of AxoGen during the 2nd quarter valued at about $125,000. BNP Paribas Financial Markets increased its stake in shares of AxoGen by 8.6% during the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after acquiring an additional 1,651 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of AxoGen by 8.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after acquiring an additional 2,204 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Price Performance

AxoGen stock opened at $13.02 on Tuesday. AxoGen has a 52 week low of $3.45 and a 52 week high of $13.35. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $10.21 and its 200 day simple moving average is $8.37. The firm has a market capitalization of $570.67 million, a PE ratio of -26.04 and a beta of 1.12.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The business had revenue of $47.91 million for the quarter, compared to analyst estimates of $43.27 million. On average, equities research analysts predict that AxoGen will post -0.33 EPS for the current fiscal year.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.